Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis Leave a reply Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market potential. Rocatinlimab’s novel approach as an investigational T-cell rebalancing therapy directly targeting the OX40 receptor expressed on pathogenic T-cells shows potential to deliver long-term disease control in patients with moderate-to-severe atopic dermatitis (msAD). Regulatory submission is planned in the first half of 2026. TOKYO and PRINCETON, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) — Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the termination of the current rocatinlimab development and commercialization collaboration with Amgen. Kyowa Kirin will regain control of the global rocatinlimab program, including regulatory filings and future commercialization. This business decision is the result of a strategic portfolio prioritization by Amgen. The companies are initiating a smooth and orderly transition of the program, with a focus on ensuring continuity for participants currently enrolled in clinical trial programs. Amgen, who has partnered with Kyowa Kirin on numerous investigational therapies over 41 years, will continue to manufacture rocatinlimab. “Kyowa Kirin is confident in the potential of rocatinlimab to address critical unmet needs for patients with moderate-to-severe atopic dermatitis who are looking for new, long-lasting options that may address the chronic nature of unpredictable flares,” said Abdul Mullick, Ph.D., President and Chief Operating Officer of Kyowa Kirin. “Rocatinlimab’s science and its highly differentiated mechanism of action targeting the OX40 receptor make it a potentially unique treatment option. We are excited to build on the strong clinical program we have established and apply our extensive clinical and commercial expertise to help make patients smile with what is a key strategic priority for Kyowa Kirin going

EF launches search for strategic partner in bid to become world’s best cycling team Leave a reply Additional investment builds on EF’s existing commitment and will go towards building Tour de France Femmes winning squad and long-term talent development on men’s and U23 squads CAMBRIDGE, Mass., Jan. 30, 2026 (GLOBE NEWSWIRE) — EF (Education First) is launching an unprecedented and unique opportunity, opening the first naming rights for EF Pro Cycling to an additional partner ready to shape the next era of professional cycling together with EF. EF will remain the team’s owner and long-term anchor partner at an unchanged level of investment. The opening of a title partner position is designed to add resources on top of EF’s existing commitment, enabling the team to compete with the largest budgets in the sport and accelerate its ambitions. This opportunity gives a partner the chance to help build the team of the future alongside EF, while gaining visibility in front of millions of fans worldwide. EF’s long-term vision is focused on three clear outcomes: Win the Tour de France Femmes within the next three years Continue building the world leading development pathway in professional cycling Win both men’s and women’s Tours de France within the next decade with riders developed through the EF Pro Cycling system “It’s rare in professional sport, and nearly unheard of in cycling, for an owner and anchor partner to commit long-term at EF’s current level and still invite an additional title partner to invest purely to make the team stronger,” says team CEO Jonathan Vaughters. “We owe a great deal to EF. They recognize the incredible opportunity we have to keep building something truly special.” Founded in 2003 on the belief that fans deserved a team they could trust, the team has won monuments, Olympic medals,